MX2014013503A - Metodo para inducir actividad udp-glucuronosiltransferasa utilizando pterostilbeno. - Google Patents
Metodo para inducir actividad udp-glucuronosiltransferasa utilizando pterostilbeno.Info
- Publication number
- MX2014013503A MX2014013503A MX2014013503A MX2014013503A MX2014013503A MX 2014013503 A MX2014013503 A MX 2014013503A MX 2014013503 A MX2014013503 A MX 2014013503A MX 2014013503 A MX2014013503 A MX 2014013503A MX 2014013503 A MX2014013503 A MX 2014013503A
- Authority
- MX
- Mexico
- Prior art keywords
- pterostilbene
- udp
- inducing
- glucuronosyltransferase
- activity
- Prior art date
Links
- 102000016354 Glucuronosyltransferase Human genes 0.000 title abstract 3
- 108010092364 Glucuronosyltransferase Proteins 0.000 title abstract 3
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 title abstract 3
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title 1
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 abstract 1
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/466,827 US8841350B2 (en) | 2011-05-11 | 2012-05-08 | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
| PCT/US2012/064993 WO2013169291A2 (en) | 2012-05-08 | 2012-11-14 | Method for inducing udp-glucuronosyltransferase activity using pterostilbene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014013503A true MX2014013503A (es) | 2015-11-13 |
Family
ID=47142275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013503A MX2014013503A (es) | 2012-05-08 | 2012-11-14 | Metodo para inducir actividad udp-glucuronosiltransferasa utilizando pterostilbeno. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8841350B2 (enExample) |
| EP (1) | EP2846785A4 (enExample) |
| JP (1) | JP2015523963A (enExample) |
| KR (1) | KR20150027081A (enExample) |
| CN (1) | CN104768543A (enExample) |
| AU (1) | AU2012379655B2 (enExample) |
| BR (1) | BR112014027646A2 (enExample) |
| CA (1) | CA2872623A1 (enExample) |
| IN (1) | IN2014DN09990A (enExample) |
| MX (1) | MX2014013503A (enExample) |
| WO (1) | WO2013169291A2 (enExample) |
| ZA (1) | ZA201408893B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160067193A1 (en) * | 2014-09-04 | 2016-03-10 | The Regents Of The University Of California | Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia |
| EP3194032B1 (en) * | 2014-09-04 | 2021-06-23 | The Regents of the University of California | Topical pterostilbene compositions for use in treating loss of barrier function in skin in burn injurys |
| WO2016200447A1 (en) * | 2015-06-10 | 2016-12-15 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
| US12134956B2 (en) | 2022-10-11 | 2024-11-05 | Halliburton Energy Services, Inc. | Liner hanger system |
| US12398624B2 (en) | 2023-07-11 | 2025-08-26 | Halliburton Energy Services, Inc. | Self-energizing seal for expandable liner hanger |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623724B2 (en) * | 1996-09-18 | 2003-09-23 | Applied Genetics Incorporated Dermatics | Dermatological compositions and methods |
| US6414037B1 (en) * | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
| DE10161253A1 (de) | 2001-12-13 | 2003-06-26 | Dragoco Gerberding Co Ag | Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren |
| FR2869229B1 (fr) | 2004-04-26 | 2006-08-25 | Sederma Soc Par Actions Simpli | Utilisation d'un inducteur des ugt par voie topique |
| ES2246165B1 (es) | 2004-07-20 | 2006-12-01 | Universitat De Valencia | Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer. |
| US8426369B2 (en) | 2006-12-07 | 2013-04-23 | Rutgers, The State University Of New Jersey | Prevention and treatment of colon cancer |
| US8509879B2 (en) | 2007-11-06 | 2013-08-13 | The Regents Of The University Of California | Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging |
| AU2009204181A1 (en) * | 2008-01-08 | 2009-07-16 | David Rubin | Method and compositions for administering resveratrol and pterostilbene |
| US20090324740A1 (en) | 2008-06-13 | 2009-12-31 | Albritton Iv Ford D | Novel nasal spray |
| US20100240767A1 (en) | 2009-03-23 | 2010-09-23 | Muhammed Majeed | Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof |
| US9737495B2 (en) | 2009-06-22 | 2017-08-22 | Indus Biotech Private Limited | Process for obtaining purified pterostilbene and methods of use thereof |
| US20110136751A1 (en) | 2009-10-06 | 2011-06-09 | Green Molecular | Use of Polyphenols in the Treatment of Cancer |
| EP2322159A1 (en) | 2009-10-30 | 2011-05-18 | Green Molecular, S.L. | Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
| US8399712B2 (en) * | 2010-02-03 | 2013-03-19 | Laurus Labs Private Limited | Pterostilbene cocrystals |
| US8883218B2 (en) * | 2010-03-26 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Anti-cancer nanoparticle compositions and methods of use |
| CN110015962B (zh) | 2011-01-28 | 2022-03-15 | 肯塔基大学研究基金会 | 茋类似物和治疗癌症的方法 |
| WO2013051459A1 (ja) * | 2011-10-02 | 2013-04-11 | キユーピー 株式会社 | ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途 |
-
2012
- 2012-05-08 US US13/466,827 patent/US8841350B2/en active Active - Reinstated
- 2012-11-14 IN IN9990DEN2014 patent/IN2014DN09990A/en unknown
- 2012-11-14 JP JP2015511433A patent/JP2015523963A/ja active Pending
- 2012-11-14 KR KR20147034337A patent/KR20150027081A/ko not_active Withdrawn
- 2012-11-14 CN CN201280074486.2A patent/CN104768543A/zh active Pending
- 2012-11-14 CA CA2872623A patent/CA2872623A1/en not_active Abandoned
- 2012-11-14 MX MX2014013503A patent/MX2014013503A/es unknown
- 2012-11-14 EP EP12876092.3A patent/EP2846785A4/en not_active Withdrawn
- 2012-11-14 AU AU2012379655A patent/AU2012379655B2/en not_active Expired - Fee Related
- 2012-11-14 WO PCT/US2012/064993 patent/WO2013169291A2/en not_active Ceased
- 2012-11-14 BR BR112014027646A patent/BR112014027646A2/pt not_active IP Right Cessation
-
2014
- 2014-09-22 US US14/493,058 patent/US10039725B2/en active Active - Reinstated
- 2014-12-04 ZA ZA2014/08893A patent/ZA201408893B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2846785A4 (en) | 2016-06-15 |
| US20150011650A1 (en) | 2015-01-08 |
| WO2013169291A3 (en) | 2015-06-18 |
| AU2012379655A1 (en) | 2014-11-20 |
| KR20150027081A (ko) | 2015-03-11 |
| IN2014DN09990A (enExample) | 2015-08-14 |
| US20120289605A1 (en) | 2012-11-15 |
| WO2013169291A2 (en) | 2013-11-14 |
| AU2012379655B2 (en) | 2018-01-18 |
| CN104768543A (zh) | 2015-07-08 |
| US10039725B2 (en) | 2018-08-07 |
| ZA201408893B (en) | 2016-08-31 |
| US8841350B2 (en) | 2014-09-23 |
| EP2846785A2 (en) | 2015-03-18 |
| CA2872623A1 (en) | 2013-11-14 |
| JP2015523963A (ja) | 2015-08-20 |
| BR112014027646A2 (pt) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501197A1 (en) | Therapeutically active compounds and their methods of use | |
| PH12014501561A1 (en) | Therapeutically active compounds and their methods of use | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
| MX377157B (es) | Preparación para usarse en el tratamiento de un cáncer positivo de gd2. | |
| PH12014502046A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| MX392388B (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe) | |
| PH12013502144A1 (en) | Multiple myeloma treatment | |
| MX361458B (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| MX2014013503A (es) | Metodo para inducir actividad udp-glucuronosiltransferasa utilizando pterostilbeno. | |
| BR112012008310A2 (pt) | métodos para tratamento de tumores cerebrais | |
| GB2525517A (en) | Topical preparation for pain relief | |
| MX386151B (es) | Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple. | |
| MX359171B (es) | Tratamiento para diabetes tipo i y tipo ii. | |
| PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
| MX364643B (es) | USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2. | |
| UA58066U (ru) | Способ лечения генитальной вирусной инфекции | |
| UA82641U (ru) | Способ лечения нейросифилиса с паренхиматозными изменениями | |
| UA69690U (ru) | Способ лечения больных с синдромом повышенной утомляемости на фоне хронической тонзиллярной инфекции |